| Quick navigation: | Home | Site Map || References | Biography || Copyright | Other copyright | Contact us | Advert | | |
Re: [ccp4bb] pointless (1.2.0) and enantiomorphic SG's |
||
- Protein crystallographyMain steps:- Protein purification- Crystallisation Special:- Programs for crystallography- X-ray detectors Basic tutorials:- Chemistry- Protein - Peptide - Amino Acids Xtal community:- CCP4BB |
CCP4bb navigationCCP4bb <-- 1999 <-- November 1999 <-- 30 November 1999Subject: Re: pointless (1.2.0) and enantiomorphic SG's From: Garib Murshudov garib {- at -} YSBL {- dot -} YORK {- dot -} AC {- dot -} UK Date: 2007-11-09 I am for it also. It is a god idea!! Garib On 9 Nov 2007, at 13:56, Ian Tickle wrote: > I like it! > > -- Ian > >> -----Original Message----- >> From: owner-ccp4bb@jiscmail.ac.uk >> [mailto:owner-ccp4bb@jiscmail.ac.uk] On Behalf Of Eleanor Dodson >> Sent: 09 November 2007 13:51 >> To: Phil Evans >> Cc: CCP4BB@jiscmail.ac.uk >> Subject: Re: [ccp4bb] pointless (1.2.0) and enantiomorphic SG's >> >> As I often say!!! The mtz format should carry point group and >> alternate >> SGs - then be upgraded when youknow the correct SG.. >> >> Eleanor >> >> Phil Evans wrote: >>> It just picks the first in the list, to store in the output >> MTZ file, >>> which can only handle one (92 < 96) >>> Phil >>> >>> >>> On 8 Nov 2007, at 22:26, Bryan W. Lepore wrote: >>> >>>> when pointless (1.2.0) finds enantiomorphic SG's, what is the >>>> criterion for 'Selecting' one over the other? >>>> >>>> e.g. i ran pointless on some tetragonal data, and the >> enantiomorphs >>>> SG92/SG96 are selected as strong candidates >>>> >>>> Spacegroup TotProb SysAbsProb Reindex >> Conditions >>>> ( 92) 0.956 0.956 00l: >>>> l=4n, h00: h=2n (zones 1,2) >>>> ( 96) 0.956 0.956 00l: >>>> l=4n, h00: h=2n (zones 1,2) >>>> >>>> ... then pointless reports : >>>> >>>> Selecting space group P 41 21 2 as solutions are enantiomorphic >>>> Best Solution space group P 41 21 2 >>>> >>>> ... is that b/c pointless can only report one, and SG92 >> came up first? >>>> >>>> -bryan >>> >>> >> >> > > > Disclaimer > This communication is confidential and may contain privileged > information intended solely for the named addressee(s). It may not > be used or disclosed except for the purpose for which it has been > sent. If you are not the intended recipient you must not review, > use, disclose, copy, distribute or take any action in reliance upon > it. If you have received this communication in error, please notify > Astex Therapeutics Ltd by emailing I.Tickle@astex-therapeutics.com > and destroy all copies of the message and any attached documents. > Astex Therapeutics Ltd monitors, controls and protects all its > messaging traffic in compliance with its corporate email policy. > The Company accepts no liability or responsibility for any onward > transmission or use of emails and attachments having left the Astex > Therapeutics domain. Unless expressly stated, opinions in this > message are those of the individual sender and not of Astex > Therapeutics Ltd. The recipient should check this email and any > attachments for the presence of computer viruses. Astex > Therapeutics Ltd accepts no liability for damage caused by any > virus transmitted by this email. E-mail is susceptible to data > corruption, interception, unauthorized amendment, and tampering, > Astex Therapeutics Ltd only send and receive e-mails on the basis > that the Company is not liable for any such alteration or any > consequences thereof. > Astex Therapeutics Ltd., Registered in England at 436 Cambridge > Science Park, Cambridge CB4 0QA under number 3751674 > > CCP4bb navigationCCP4bb <-- 1999 <-- November 1999 <-- 30 November 1999 |
|
| ProteinCrystallography.org: Copyright 2006-2010 by Quid United Ltd |